Reimagining digital healthcare worldwide Reimagining digital healthcare worldwide How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
The impact of carbon reduction projects The impact of carbon reduction projects Boehringer Ingelheim voluntarily contributes to carbon reduction projects that benefit sustainable development.
Immunology Respiratory Research Immunology Respiratory Research Find out more about our research and development in Immunology & Respiratory diseases
Boehringer Ingelheim Second Transforming Science Day Boehringer Ingelheim Second Transforming Science Day World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day
The power of our people The power of our people Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Health equity for underserved communities Health equity for underserved communities Introducing initiatives that improve access to healthcare for underserved communities
T-cell engagers: Reawakening T-cells to fight cancer T-cell engagers: Reawakening T-cells to fight cancer Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Supporting Rabies Free Pakistan Indus Hospital Supporting Rabies Free Pakistan Indus Hospital Rabies endangers thousands of human lives in Pakistan every year. We provide green collars and vaccines to improve situation.
Social innovation: catalyst for sustainable health solutions Social innovation: catalyst for sustainable health solutions Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments License to develop new fibro-inflammatory disease treatments
Veterinary oncology - cancer treatment Veterinary oncology - cancer treatment Our R&D team's efforts toward finding new cancer treatments for pets
Partnership to further develop pet market in China Partnership to further develop pet market in China Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
New cancer research building: Boosting innovation in oncology New cancer research building: Boosting innovation in oncology With our new cancer research building in Vienna, we’ll advance our oncology pipeline and strengthen our commitment to innovation and collaboration.
Disentangling fibrosis Disentangling fibrosis Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
From social worker to joining the pharmaceutical industry From social worker to joining the pharmaceutical industry Patient centricity: How Miyuki Ono contributes to our diverse workforce with her experience as a social worker and helps patients in Japan
Algorithms to battle heartworm disease Algorithms to battle heartworm disease Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Boehringer acquires T3 Pharma Boehringer acquires T3 Pharma Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
Looking behind the scenes of Afrika Kommt! Looking behind the scenes of Afrika Kommt! Looking behind the scenes of Afrika Kommt! with Sabine and Eunice. I in D&I audio interview with reflections on a program designed to build bridges.
preventive care cat veterinarian preventive care cat veterinarian What can we all, cat owners or veterinarians, do to promote cat health? Click to find out!
Introducing CIAS Introducing CIAS Schizophrenia affects 1 in 100, yet the condition can be misunderstood due to some symptoms being overlooked, such as cognitive impairment
Fast-Track-Designation-NASH Fast-Track-Designation-NASH Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Monoclonal antibodies Boehringer Ingelheim and Invetx Monoclonal antibodies Boehringer Ingelheim and Invetx Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics